SCHEMBL364950

SCHEMBL364950

CS(=O)(=O)NC(=O)c1ccc(OCc2ccc(F)c(F)c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.66
MAOA P21397 1/20 0.66
PPARA Q07869 1/20 0.50
SCN9A Q15858 3/20 0.48
BCL2L1 Q07817 3/20 0.47
MCL1 Q07820 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
SCN5A Q14524 1/20 0.47
MRGPRX4 Q96LA9 2/20 0.46
SENP7 Q9BQF6 2/20 0.46
SCN3A Q9NY46 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
NPC1 O15118 1/20 0.45
CASP3 P42574 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL365348 0.89 SCN9A (0.56) MAOBMAOASCN9ABCL2L1MCL1
SCHEMBL364615 0.88 MAOA (0.51) MAOBMAOASCN9ABCL2L1MCL1
SCHEMBL366812 0.86 MAOB (0.63) MAOBSCN9ABCL2L1MCL1ALDH1A1
SCHEMBL14890621 0.85 GSK3B (0.55) MAOBSCN9ABCL2L1MCL1ALDH1A1
SCHEMBL366081 0.83 MAOA (0.63) MAOBMAOAPPARASCN9ABCL2L1
SCHEMBL365210 0.83 MAOA (0.63) MAOBMAOAPPARASCN9ABCL2L1
SCHEMBL10203178 0.82 SCN9A (0.66) MAOBMAOASCN9ABCL2L1MCL1
SCHEMBL371154 0.82 MRGPRX4 (0.62) MAOBMAOASCN9ASCN5AMRGPRX4
SCHEMBL367348 0.82 BCL2L1 (0.57) MAOBMAOASCN9ABCL2L1MCL1
SCHEMBL365645 0.82 ALDH1A1 (0.70) SCN9ABCL2L1MCL1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A MAOB 3660/4885MAOA 3705/4885PPARA 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.